Dual-Contrast Molecular Imaging Allows Noninvasive Characterization of Myocardial Ischemia/Reperfusion Injury After Coronary Vessel Occlusion in Mice by Magnetic Resonance Imaging

Abstract

Background-Inflammation and myocardial necrosis play important roles in ischemia/reperfusion injury after coronary artery occlusion and recanalization. The detection of inflammatory activity and the extent of myocardial necrosis itself are of great clinical and prognostic interest. We developed a dual, noninvasive imaging approach using molecular magnetic resonance imaging in an in vivo mouse model of myocardial ischemia and reperfusion. Methods and Results-Ischemia/reperfusion injury was induced in 10-week-old C57BL/6N mice by temporary ligation of the left anterior descending coronary artery. Activated platelets were targeted with a contrast agent consisting of microparticles of iron oxide (MPIOs) conjugated to a single-chain antibody directed against a ligand-induced binding site (LIBS) on activated glycoprotein IIb/IIIa (LIBS-MPIOs). After injection and imaging of LIBS-MPIOs, late gadolinium enhancement was used to depict myocardial necrosis; these imaging experiments were also performed in P2Y 12 −/− mice. All imaging results were correlated to immunohistochemistry findings. Activated platelets were detectable by magnetic resonance imaging via a significant signal effect caused by LIBS-MPIOs in the area of left anterior descending coronary artery occlusion 2 hours after reperfusion. In parallel, late gadolinium enhancement identified the extent of myocardial necrosis. Immunohistochemistry confirmed that LIBS-MPIOs bound significantly to microthrombi in reperfused myocardium. Only background binding was found in P2Y 12 −/− mice. Conclusions-Dual molecular imaging of myocardial ischemia/reperfusion injury allows characterization of platelet-driven inflammation by LIBS-MPIOs and myocardial necrosis by late gadolinium enhancement. This noninvasive imaging strategy is of clinical interest for both diagnostic and prognostic purposes and highlights the potential of molecular magnetic resonance imaging for characterizing ischemia/reperfusion injury. (Circulation. 2014;130:676-687.)

A Unique Recombinant Fluoroprobe Targeting Activated Platelets Allows In Vivo Detection of Arterial Thrombosis and Pulmonary Embolism Using a Novel Three-Dimensional Fluorescence Emission Computed Tomography (FLECT) Technology

“…Consequently, it provides a better signal to background noise ratio and better access to target protein/cells. We have previously employed this scFv in various molecular imaging modalities such as intravital microscopy 13, ultrasound 14, PET 12 and MRI 15-18 of small animals. In these in viv o studies, no inhibitions of platelet aggregation, or bleeding prolongation or complications were observed with the dose used of the anti-activated-GPIIb/IIIa scFv.…”

High field magnetic resonance imaging of rodents in cardiovascular research

“…After labeling of stem cells with these small biocompatible crystalline magnetite structures, cell engraftment, differentiation and viability can be noninvasively monitored thanks to the high sensitivity of SPIONs for MRI [26]. If so far, cardiovascular applications in mice at HF remain scarce [36, 96,111,133,165], it represents a promising approach for the study and follow-up of stem cell therapy in the field of cardiology.…”

Immune-mediated and lipid-mediated platelet function in atherosclerosis

“…In recent years, substantial advances were made in the development of targeted magnetic agents for cardiovascular imaging [189-192,193 & ]. von Elverfeldt et al [185] were able to image the extent of myocardial ischemia/reperfusion injury after coronary vessel occlusion using a contrast agent, consisting of microparticles of iron oxide (MPIOs) conjugated to a single-chain antibody directed against activated platelets, via MRI. Jacobin-Valat et al used the Versatile UltraSmall SuperParamagnetic Iron Oxide (VUSPIO) platform, based on 7.5-nm-sized magnetic cores (maghemite g-Fe 2 O 3 ), that enhances contrast in MRI.…”